QuorumCivic. Hidden in plain sight Get the app
Bill intelligence

Congress designates hepatitis B awareness day, spotlighting vaccine gaps

H.Res. 362 — Expressing support for the designation of April 30, 2025, as "National Adult Hepatitis B Vaccination Awareness Day". · Filed by Hank Johnson (D-GA) · 6 cosponsors · Introduced Apr 30, 2025 · Referred to committee

95%
Transparency
Typical bill: 82%
8/100
Hidden-provision risk
Typical bill: 15/100
Public Health Awareness Resolution

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

This resolution expresses congressional support for designating April 30, 2025, as 'National Adult Hepatitis B Vaccination Awareness Day.' It documents the public health burden of hepatitis B—particularly among communities of color, LGBTQ+ populations, and people affected by the opioid crisis—and highlights that safe, effective vaccines exist but only 30% of U.S. adults are vaccinated. The resolution calls attention to rising acute hepatitis B cases linked to injection drug use and advocates for increased adult vaccination efforts.

Why we flagged it

This is a symbolic House resolution designating a single day for hepatitis B vaccination awareness. It contains no legislative mandates, appropriations, or regulatory changes—purely an expression of support for public health messaging.

What the text implies

  • May indirectly boost demand for hepatitis B vaccines among adult populations, benefiting vaccine manufacturers and creating market expansion opportunities beyond the existing pediatric vaccination program.
  • Highlights disparities in vaccination rates among communities of color and vulnerable populations, potentially driving targeted public health interventions that could expose systemic inequities in healthcare access and provider networks.

The full analysis lists 5 implications of this text.

Who stands to gain

Hepatitis B vaccine manufacturers (Pfizer, Merck, GSK); Dialysis service providers; Infectious disease treatment providers

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the bill title — full-text pass pending · 119th Congress · public record